Loading…
Loading…
Medicure Inc. (MPH:CA) Q2 2026 Earnings Call Prepared Remarks Transcript
WINNIPEG, MB / ACCESS Newswire / August 14, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended June 30, 2026 and will have a conference call to present the Financial Results on August 17, 2026 at 8:30 am Eastern Time. Quarter Ended June 30, 2026 Highlights: Recorded total net revenue of $7.4 million during the period ended June 30, 2026 compared to $6.7 million for the period ended June 30, 2025 and; Recorded total net revenue from the sale of ZYPITAMAG® of $2.1 million ($850,000 through the traditional insured channels, and $1.2 million through Marley Drug) during the period ended June 30, 2026 compared to $1.7 million ($751,000 through the traditional insured channels, and $908,000 through Marley Drug) for the period ended June 30, 2025 and; Recorded total net revenue from the sale of AGGRASTAT® of $661,000 during the period ended June 30, 2026 compared to $1.7 million during the period ended June 30, 2025 and; The Pharmacy Business Segment, which includes Marley Drug, and the Company's two 2025 acquired pharmacies, Gateway Medical Pharmacy and West Olympia Pharmacy, recorded total net revenue of $5.9 million ($1.2 million from sales of ZYPITAMAG®, and $4.7 million from other pharmacy revenue) during the period ended June 30, 2026 compared to net revenue of $4.2 million ($908,000 from sales of ZYPITAMAG® , and $3.3 million from other pharmacy revenue) during the period ended June 30, 2025 and; Medicure invested $608,000 in research and development during the period ended June 30, 2026, underscoring our commitment to advancing innovative therapies, such as the Phase 3 trial of Medicure's investigational product MC-1 for the treatment of PNPO deficiency and delivering long-term value to patients and shareholders, and; Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA1) for the period ended June 30, 2026 was $172,000 compared to negative adjusted EBITDA of $28,000 for the period ended June 30, 2025 and; Net loss for the period ended June 30, 2026 was $1.4 million or $0.14 per share compared to a net loss of $786,000 or $0.08 per share for the period ended June 30, 2025; the net loss is due in large part to the Company recording a liability of $864,000 pertaining to Centers for Medicare and Medicaid Services ("CMS"), in addition non-cash expenses including $669,000 of amortization on the assets relating to the purchase of ZYPITAMAG® and the Pharmacy Business Segment.
Takeda Pharmaceutical (NYSE: TAK - Get Free Report) and Medicure (OTCMKTS:MCUJF - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, risk, earnings, analyst recommendations, dividends and institutional ownership. Analyst Ratings This is a breakdown of current recommendations
WINNIPEG, MB / ACCESS Newswire / July 3, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announced that Haaris Uddin has resigned from his role as Chief Financial Officer ("CFO") of the Company, effective July 24, 2026, to pursue an opportunity in an unrelated industry. James Kinley, who was the previous CFO of Medicure from 2011 to 2021 and is a current member of the Company's board of directors, has been named interim CFO and will assume the role upon Mr.
Medicure Inc. (MPH:CA) Q1 2026 Earnings Call Prepared Remarks Transcript
WINNIPEG, MB / ACCESS Newswire / May 21, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended March 31, 2026 and will have a conference call to present the Financial Results on May 25, 2026 at 8:30 am Eastern Time. Quarter Ended March 31, 2026 Highlights: Recorded total net revenue of $7.9 million during the period ended March 31, 2026 compared to $5.4 million for the period ended March 31, 2025 and; Recorded total net revenue from the sale of ZYPITAMAG® of $2.3 million ($1.3 million through the traditional insured channels, and $1.0 million through Marley Drug) during the period ended March 31, 2026 compared to $1.4 million ($519,000 through the traditional insured channels, and $918,000 through Marley Drug) for the period ended March 31, 2025 and; Recorded total net revenue from the sale of AGGRASTAT® of $979,000 during the period ended March 31, 2026 compared to $1.7 million during the period ended March 31, 2025 and; The Pharmacy Business Segment, which includes Marley Drug, and the Company's two recently acquired pharmacies (purchased in 2025), Gateway Medical Pharmacy and West Olympia Pharmacy, recorded total net revenue of $5.7 million ($1.0 million from sales of ZYPITAMAG®, and $4.7 million from other pharmacy revenue) during the period ended March 31, 2026 compared to net revenue of $3.3 million ($918,000 from sales of ZYPITAMAG®, and $2.3 million from other pharmacy revenue) during the period ended March 31, 2025 and; Medicure invested $855,000 in research and development during the period ended March 31, 2026, underscoring our commitment to advancing innovative therapies, such as the Phase 3 trial of Medicure's investigational product MC-1 for the treatment of PNPO deficiency and delivering long-term value to patients and shareholders, and; Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA1) for the period ended March 31, 2026 was $280,000 compared to adjusted EBITDA of $28,000 for the period ended March 31, 2025 and; Net loss for the period ended March 31, 2026 was $406,000 or $0.04 per share compared to a net loss of $694,000 or $0.07 per share for the period ended March 31, 2025; the net loss is due in large part to $855,000 invested into research and development, primarily relating to MC-1 for the treatment of PNPO deficiency, in addition to non-cash expenses including $644,000 of amortization on the assets relating to the purchase of ZYPITAMAG® and the Pharmacy Business Segment.
WINNIPEG, MB / ACCESS Newswire / May 21, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, announces the voting results from its Annual General Meeting of shareholders (the "Meeting") held today, including the appointment of Kerrie Hayes to the board of directors of the Company. A total of 5,237,796 common shares (representing 50.19% of the votes attached to all outstanding common shares of the Company as at the record date) were voted in person or by proxy at the Meeting.
Medicure Inc. (MPH:CA) Q4 2025 Earnings Call Prepared Remarks Transcript